Targeting HRD and BRCA: The Expanding Role of PARP Inhibitors in Ovarian Cancer Treatment by CheckRare Staff| Published on: Feb 20, 2026

Targeting HRD and BRCA: The Expanding Role of PARP Inhibitors in Ovarian Cancer Treatment by CheckRare Staff| Published on: Feb 20, 2026 PRIMA Clinical Trial Bradley J. Monk, MD, Medical Director, Florida Cancer Specialists and Research Institute, West Palm Beach, and Founder of GOG Partners, discusses the clinical advances in the treatment of ovarian cancer, including research using PARP inhibitors, which can change standard of care for women with certain tumor types. https://checkrare.com/parp-inhibitors-in-ovarian-cancer-treatment/